36 / 43
Median OS,
mo (95% CI)
HR
(95% CI)
Nivo (n = 52)
7.7 (3.1, 13.8)
0.56
(0.33, 0.95)
IC (n = 26)
3.3 (2.1, 6.4)
Months
OS (%)
0
3
6
9
12
15
18
21
24
27
0
10
20
30
40
50
60
70
80
100
90
52
34
27
22
18
9
7
5
1
0
26
16
10
6
4
1
1
1
0
0
Nivo
IC
No. of patients at risk
Nivo
IC
39.2%
15.4%
12-mo OS =
Nivo = nivolumab
OS 1L R/M nivolumab or IC after platinum-based
Therapy in the primary/adjuvant setting
36